NO20042209L - Fremgangsmater og anordninger for fremstilling av proteiner med forutbestemte post-translasjonelle modifikasjoner - Google Patents

Fremgangsmater og anordninger for fremstilling av proteiner med forutbestemte post-translasjonelle modifikasjoner

Info

Publication number: NO20042209L
Authority: NO; Norway
Prior art keywords: translational modifications; post; mammalian cells; predetermined post; present
Prior art date: 2001-10-29

Application number

NO20042209A

Other languages

English (en)

Norwegian (no)

Inventor

Abraham Bout

Johan Christiaan Kapteyn

Petrus Christianus Joh Passier

Ronald Hendrik Peter Brus

Dirk Jan Elbertus Opstelten

Original Assignee

Crucell Holland Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-29

Filing date

2004-05-28

Publication date

2004-07-28

2001-10-29 Priority claimed from PCT/NL2001/000792 external-priority patent/WO2003050286A1/fr

2002-04-19 Priority claimed from PCT/NL2002/000257 external-priority patent/WO2003089468A1/fr

2004-05-28 Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv

2004-07-28 Publication of NO20042209L publication Critical patent/NO20042209L/no

Links

230000004481 post-translational protein modification Effects 0.000 title abstract 6
238000000034 method Methods 0.000 title abstract 4
102000004169 proteins and genes Human genes 0.000 title abstract 3
108090000623 proteins and genes Proteins 0.000 title abstract 3
210000004962 mammalian cell Anatomy 0.000 abstract 5
102000003951 Erythropoietin Human genes 0.000 abstract 3
108090000394 Erythropoietin Proteins 0.000 abstract 3
229940105423 erythropoietin Drugs 0.000 abstract 3
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 abstract 3
230000013595 glycosylation Effects 0.000 abstract 2
238000006206 glycosylation reaction Methods 0.000 abstract 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000001537 neural effect Effects 0.000 abstract 1
229920001542 oligosaccharide Polymers 0.000 abstract 1
150000002482 oligosaccharides Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Zoology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Virology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Cardiology (AREA)
General Engineering & Computer Science (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)

NO20042209A 2001-10-29 2004-05-28 Fremgangsmater og anordninger for fremstilling av proteiner med forutbestemte post-translasjonelle modifikasjoner NO20042209L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
PCT/NL2001/000792 WO2003050286A1 (fr)	2001-10-29	2001-10-29	Procedes et moyens de production de proteines a modifications post-traductionnelles
PCT/NL2002/000257 WO2003089468A1 (fr)	2002-04-19	2002-04-19	Methodes et moyens de production de proteines avec des modifications post-traductionnelles preetablies
PCT/NL2002/000686 WO2003038100A1 (fr)	2001-10-29	2002-10-29	Procedes et moyens de fabrication de proteines presentant des modifications post-traductionnelles predeterminees

Publications (1)

Publication Number	Publication Date
NO20042209L true NO20042209L (no)	2004-07-28

Family

ID=26642018

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20042209A NO20042209L (no)	2001-10-29	2004-05-28	Fremgangsmater og anordninger for fremstilling av proteiner med forutbestemte post-translasjonelle modifikasjoner

Country Status (14)

Country	Link
US (3)	US7304031B2 (fr)
EP (2)	EP2292770B1 (fr)
JP (1)	JP4583029B2 (fr)
CN (1)	CN100347306C (fr)
AT (1)	ATE542904T1 (fr)
AU (1)	AU2002335585B2 (fr)
BR (1)	BR0213402A (fr)
CA (2)	CA2465007C (fr)
DK (1)	DK1440157T3 (fr)
EA (2)	EA008220B1 (fr)
ES (1)	ES2381104T3 (fr)
IL (3)	IL161674A (fr)
NO (1)	NO20042209L (fr)
WO (1)	WO2003038100A1 (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE445705T1 (de)	1995-06-15	2009-10-15	Crucell Holland Bv	Verpackungssysteme für humane rekombinante adenoviren zur gentherapie
US8236561B2 (en)	1999-04-15	2012-08-07	Crucell Holland B.V.	Efficient production of IgA in recombinant mammalian cells
US6855544B1 (en)	1999-04-15	2005-02-15	Crucell Holland B.V.	Recombinant protein production in a human cell
US20050164386A1 (en) *	1999-04-15	2005-07-28	Uytdehaag Alphonsus G.	Overexpression of enzymes involved in post-translational protein modifications in human cells
US7604960B2 (en)	1999-04-15	2009-10-20	Crucell Holland B.V.	Transient protein expression methods
US7297680B2 (en)	1999-04-15	2007-11-20	Crucell Holland B.V.	Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7521220B2 (en)	1999-11-26	2009-04-21	Crucell Holland B.V.	Production of vaccines
US7192759B1 (en)	1999-11-26	2007-03-20	Crucell Holland B.V.	Production of vaccines
US7527961B2 (en)	1999-11-26	2009-05-05	Crucell Holland B.V.	Production of vaccines
US7767643B2 (en)	2000-12-29	2010-08-03	The Kenneth S. Warren Institute, Inc.	Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en)	2000-12-29	2003-04-17	Michael Brines	Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
EA008220B1 (ru) *	2001-10-29	2007-04-27	Круселл Холланд Б.В.	Композиция, включающая эритропоэтинподобные молекулы, и способы ее применения
NZ533124A (en)	2001-12-07	2005-11-25	Crucell Holland B	Production of viruses, viral isolates and vaccines
US8524477B2 (en)	2002-10-29	2013-09-03	Crucell Holland B.V.	Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
AU2005223371B2 (en) *	2004-03-17	2011-06-09	Crucell Holland B.V.	Novel assay for the separation and quantification of hemagglutinin antigens
EP1844068A4 (fr) *	2005-01-25	2009-09-30	Apollo Life Sciences Ltd	Molécules et leurs molécules chimériques
CN101247822B (zh) *	2005-06-01	2012-10-17	新潟Tlo株式会社	含有epo衍生物的血液相关疾病的治疗剂
AR053416A1 (es) *	2005-11-10	2007-05-09	Protech Pharma S A	Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
CA2628725A1 (fr) *	2005-11-15	2007-05-31	Glycofi, Inc.	Production de glycoproteines a o-glycosylation reduite
US7642078B2 (en)	2005-12-28	2010-01-05	Crucell Holland B.V.	Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
US20150038413A1 (en)	2006-02-03	2015-02-05	Opko Biologics Ltd.	Long-acting polypeptides and methods of producing and administering same
US20140113860A1 (en)	2006-02-03	2014-04-24	Prolor Biotech Ltd.	Long-acting polypeptides and methods of producing and administering same
US8946155B2 (en)	2006-02-03	2015-02-03	Opko Biologics Ltd.	Long-acting polypeptides and methods of producing and administering same
US10351615B2 (en)	2006-02-03	2019-07-16	Opko Biologics Ltd.	Methods of treatment with long-acting growth hormone
US7553941B2 (en) *	2006-02-03	2009-06-30	Modigene Inc	Long-acting polypeptides and methods of producing same
US10221228B2 (en)	2006-02-03	2019-03-05	Opko Biologics Ltd.	Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en)	2006-02-03	2016-02-02	Opko Biologics Ltd.	Long-acting coagulation factors and methods of producing same
US8048849B2 (en)	2006-02-03	2011-11-01	Modigene, Inc.	Long-acting polypeptides and methods of producing same
WO2007098548A1 (fr) *	2006-03-01	2007-09-07	Apollo Life Sciences Limited	Molécule et chimères de cette molécule
WO2007142288A1 (fr)	2006-06-07	2007-12-13	The University Of Tokushima	Traitement d'une maladie ischémique à l'aide d'érythropoïétine
CN101505788B (zh)	2006-08-22	2013-06-26	中外制药株式会社	周围神经病变的预防和/或治疗药
AR065613A1 (es)	2007-03-09	2009-06-17	Chugai Pharmaceutical Co Ltd	Agentes de proteccion para organos transplantados
AU2008243007A1 (en) *	2007-04-16	2008-10-30	Momenta Pharmaceuticals, Inc.	Characterization of N-glycans using exoglycosidases
TWI488640B (zh)	2008-04-16	2015-06-21	菲瑞茵國際中心股份有限公司	藥學製劑
US8138092B2 (en)	2009-01-09	2012-03-20	Lam Research Corporation	Spacer formation for array double patterning
US9663778B2 (en)	2009-07-09	2017-05-30	OPKO Biologies Ltd.	Long-acting coagulation factors and methods of producing same
US12203113B2 (en)	2009-07-09	2025-01-21	Opko Biologics Ltd.	Long-acting coagulation factors and methods of producing same
TWI532495B (zh)	2009-10-05	2016-05-11	菲瑞茵國際中心股份有限公司	藥學製劑
CN103619358B (zh)	2011-03-31	2017-02-15	辉凌公司	药物制剂
WO2013067322A1 (fr) *	2011-11-03	2013-05-10	Stc Biologics, Inc.	Procédé de détermination de propriétés pharmacologiques de protéines recombinantes
JP2015520128A (ja)	2012-04-19	2015-07-16	オプコバイオロジクスリミテッド	長時間作用性オキシントモジュリン変異体とその作製方法
US9790268B2 (en)	2012-09-12	2017-10-17	Genzyme Corporation	Fc containing polypeptides with altered glycosylation and reduced effector function
ES2882890T3 (es)	2012-11-20	2021-12-03	Opko Biologics Ltd	Método para aumentar el volumen hidrodinámico de polipéptidos mediante la unión a péptidos carboxi terminales de la gonadotrofina
IL289918B2 (en)	2013-03-11	2025-07-01	Genzyme Corp	Site-specific antibody-drug conjugation through glycoengineering
US20150158926A1 (en)	2013-10-21	2015-06-11	Opko Biologics, Ltd.	Long-acting polypeptides and methods of producing and administering same
CA2954066A1 (fr) *	2014-07-01	2016-01-07	Stc Biologics, Inc.	Procede pour la mise au point de proteines recombinantes presentant une similarite de type empreinte par rapport au produit de reference
WO2016092550A2 (fr)	2014-12-10	2016-06-16	Opko Biologics Ltd.	Méthodes de production de polypeptides modifiés par des ctp à action prolongée
EP3988113A1 (fr)	2015-06-19	2022-04-27	OPKO Biologics Ltd.	Facteurs de coagulation à action prolongée et ses procédés de production
BR112019000610A2 (pt)	2016-07-11	2019-07-02	Opko Biologics Ltd	fator vii de coagulação de longa ação e métodos de produção do mesmo
CA3026863A1 (fr) *	2016-07-12	2018-01-18	Hexal Ag	Glycoproteine a taux d'acetylation reduit de residus d'acide sialique
US11124579B2 (en) *	2017-03-29	2021-09-21	Agency For Science, Technology And Research	Anti oligosaccharide antibody
WO2019075053A1 (fr) *	2017-10-11	2019-04-18	Elanco Us Inc.	Variants du g-csf porcins et leurs utilisations
CN111514279B (zh) *	2020-06-16	2023-07-18	温州医科大学附属第二医院（温州医科大学附属育英儿童医院）	神经营养因子3在制备治疗男性性腺功能减退症的药物中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1991005867A1 (fr)	1989-10-13	1991-05-02	Amgen Inc.	Isoformes d'erythropoietine
US5789247A (en) *	1994-04-01	1998-08-04	Ballay; Annick	Expression in non-tumoral human lymphoblastoid lines with an integrative vector
ATE445705T1 (de)	1995-06-15	2009-10-15	Crucell Holland Bv	Verpackungssysteme für humane rekombinante adenoviren zur gentherapie
US6783980B2 (en) *	1995-06-15	2004-08-31	Crucell Holland B.V.	Packaging systems for human recombinant adenovirus to be used in gene therapy
CA2221819A1 (fr) *	1997-03-27	1998-09-27	Thomas A. Gigliatti	Vecteurs d'expression d'insectes
ATE290091T1 (de) *	1997-03-27	2005-03-15	Univ British Columbia	Insekten-expressionsvektoren
US6929946B1 (en) *	1998-11-20	2005-08-16	Crucell Holland B.V.	Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
CZ20013695A3 (cs)	1999-04-13	2002-02-13	Kenneth S. Warren Laboratories	Farmaceutický prostředek
ES2237420T5 (es) *	1999-04-15	2010-03-03	Crucell Holland B.V.	Produccion de proteina recombinante en una celula humana.
US6855544B1 (en) *	1999-04-15	2005-02-15	Crucell Holland B.V.	Recombinant protein production in a human cell
US7297680B2 (en) *	1999-04-15	2007-11-20	Crucell Holland B.V.	Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US20050164386A1 (en) *	1999-04-15	2005-07-28	Uytdehaag Alphonsus G.	Overexpression of enzymes involved in post-translational protein modifications in human cells
US6913922B1 (en) *	1999-05-18	2005-07-05	Crucell Holland B.V.	Serotype of adenovirus and uses thereof
FI109811B (fi) *	2000-09-26	2002-10-15	Medicel Oy	Menetelmä GDP-L-fukoosin valmistamiseksi ja menetelmässä käytettäviä välineitä
DE10056136A1 (de)	2000-11-07	2002-05-16	Nemod New Modalities	Verwendung von Schwangerschaftsproteinen, Liposomen, nativen Muzin-Fragmenten und Mimikry-Verbindungen zur Behandlung und Prophylaxe von entzündlichen Erkrankungen, zur Verhinderung der Metastasierung und zur Prophylaxe von Tumorerkrankungen
US7473767B2 (en)	2001-07-03	2009-01-06	The Institute For Systems Biology	Methods for detection and quantification of analytes in complex mixtures
EP2305312B1 (fr) *	2001-10-10	2015-03-04	ratiopharm GmbH	Remodelage et glycoconjugation de l'hormone folliculo-stimulante (FSH)
EA008220B1 (ru) *	2001-10-29	2007-04-27	Круселл Холланд Б.В.	Композиция, включающая эритропоэтинподобные молекулы, и способы ее применения
PT2314629E (pt) *	2002-07-18	2014-01-22	Merus B V	Produção recombinante de misturas de anticorpos
AU2005223371B2 (en) *	2004-03-17	2011-06-09	Crucell Holland B.V.	Novel assay for the separation and quantification of hemagglutinin antigens
US7183371B2 (en) *	2004-11-01	2007-02-27	General Electric Company	Method for making polycarbonate
US20080139608A1 (en) *	2006-12-06	2008-06-12	Universiteit Leiden	2,6,8, Trisubstituted 1-deazapurines and their different uses

2002
- 2002-10-29 EA EA200400605A patent/EA008220B1/ru not_active IP Right Cessation
- 2002-10-29 EP EP10177590.6A patent/EP2292770B1/fr not_active Expired - Lifetime
- 2002-10-29 EP EP02770322A patent/EP1440157B1/fr not_active Expired - Lifetime
- 2002-10-29 EA EA200602163A patent/EA012340B1/ru not_active IP Right Cessation
- 2002-10-29 WO PCT/NL2002/000686 patent/WO2003038100A1/fr not_active Ceased
- 2002-10-29 CA CA2465007A patent/CA2465007C/fr not_active Expired - Fee Related
- 2002-10-29 ES ES02770322T patent/ES2381104T3/es not_active Expired - Lifetime
- 2002-10-29 CA CA2756610A patent/CA2756610C/fr not_active Expired - Fee Related
- 2002-10-29 CN CNB028216903A patent/CN100347306C/zh not_active Expired - Fee Related
- 2002-10-29 DK DK02770322.2T patent/DK1440157T3/da active
- 2002-10-29 US US10/494,140 patent/US7304031B2/en not_active Expired - Fee Related
- 2002-10-29 AU AU2002335585A patent/AU2002335585B2/en not_active Ceased
- 2002-10-29 BR BR0213402-0A patent/BR0213402A/pt not_active IP Right Cessation
- 2002-10-29 JP JP2003540365A patent/JP4583029B2/ja not_active Expired - Fee Related
- 2002-10-29 AT AT02770322T patent/ATE542904T1/de active
2004
- 2004-04-29 IL IL161674A patent/IL161674A/en not_active IP Right Cessation
- 2004-05-28 NO NO20042209A patent/NO20042209L/no not_active Application Discontinuation
2007
- 2007-01-24 US US11/657,202 patent/US7785833B2/en not_active Expired - Fee Related
- 2007-08-01 US US11/888,776 patent/US7696157B2/en not_active Expired - Fee Related
2009
- 2009-10-21 IL IL201674A patent/IL201674A/en not_active IP Right Cessation
- 2009-10-21 IL IL201673A patent/IL201673A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
EA012340B1 (ru)	2009-10-30
US20050164917A1 (en)	2005-07-28
US20070117742A1 (en)	2007-05-24
ES2381104T3 (es)	2012-05-23
CA2465007A1 (fr)	2003-05-08
US7696157B2 (en)	2010-04-13
IL161674A (en)	2014-06-30
BR0213402A (pt)	2004-10-13
EP2292770A3 (fr)	2012-12-19
ATE542904T1 (de)	2012-02-15
CA2756610C (fr)	2015-08-25
DK1440157T3 (da)	2012-05-07
JP4583029B2 (ja)	2010-11-17
CN100347306C (zh)	2007-11-07
EP2292770B1 (fr)	2014-11-26
US7785833B2 (en)	2010-08-31
EP2292770A2 (fr)	2011-03-09
CA2465007C (fr)	2012-01-17
IL201674A (en)	2013-10-31
AU2002335585B2 (en)	2007-08-16
JP2005507426A (ja)	2005-03-17
EA200602163A1 (ru)	2007-04-27
IL201673A (en)	2013-10-31
CN1578838A (zh)	2005-02-09
EA200400605A1 (ru)	2004-08-26
EP1440157A1 (fr)	2004-07-28
US7304031B2 (en)	2007-12-04
EP1440157B1 (fr)	2012-01-25
US20080032922A1 (en)	2008-02-07
EA008220B1 (ru)	2007-04-27
CA2756610A1 (fr)	2003-05-08
WO2003038100A1 (fr)	2003-05-08

Legal Events

Date	Code	Title	Description
2013-07-15	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20042209L (no)	2004-07-28	Fremgangsmater og anordninger for fremstilling av proteiner med forutbestemte post-translasjonelle modifikasjoner
DE59608743D1 (de)	2002-03-21	Verfahren zur herstellung von rekombinanten proteinen in e. coli mittels hochzelldichte-fermentation
DE68921364D1 (de)	1995-04-06	Verfahren zur Herstellung von Proteinen mittels rekombinanter DNA.
ATE405644T1 (de)	2008-09-15	Verfahren zur herstellung und reinigung von erythropoietin
DE69434578D1 (de)	2006-01-26	Expressionsvektoren die für bispezifische Proteine kodieren, und Verfahren zur Herstellung von biologisch-aktiven bispezifischen Fusionsproteine in Zellen von Säugertieren
ATE294229T1 (de)	2005-05-15	Verfahren zur trocknung von kompetenten zellen
DK0939767T3 (da)	2006-10-09	Procin faktor VIII og hybrider deraf
DE69920747D1 (de)	2004-11-04	Methode zur herstellung von rekombinanten zellen
DE3486179D1 (de)	1993-08-26	Verfahren zur herstellung vielkettige polypeptide oder proteine.
NO911688D0 (no)	1991-04-29	Neurotrophin-3, en ny neurotrofisk faktor relatert til neurovekstfaktor og hjerne-avledet neurotrofisk faktor.
ATE500331T1 (de)	2011-03-15	Verfahren zur gleichzeitigen herstellung von multiplen proteinen; vektoren und zellen, die hierfür verwendung finden
FR2782323B1 (fr)	2002-01-11	Procede de production in vitro de sequences polynucleotidiques recombinees, banques de sequences et sequences ainsi obtenues
KR910004803A (ko)	1991-03-29	간의 실질 세포 성장 인자, 이를 코딩하는 유전자, 이 인자를 생산하는 방법, 및 이 인자를 생산하는 형질전환체
DE69632887D1 (de)	2004-08-19	Verfahren zur zweckmässige Herstellung von Transglutaminase durch DNA-Rekombination
ATE397061T1 (de)	2008-06-15	Verfahren zur herstellung von proteinen
ATE424410T1 (de)	2009-03-15	Interleukin-19.
ATE433486T1 (de)	2009-06-15	Durchmusterung von bibliotheken exprimierter dna in filamentösen pilzen mit hoher durchsatzrate
PT1025245E (pt)	2006-08-31	Criacao rapida de linhas celulares estaveis de mamifero produzindo elevados iiveis de proteinas recombinantes
ATE328102T1 (de)	2006-06-15	Verfahren zur herstellung von proteine
ATE220714T1 (de)	2002-08-15	Verfahren zur herstellung von proteinen
DE60139113D1 (de)	2009-08-13	18477, eine menschliche proteinkinase und deren verwendung
DE69425809D1 (de)	2000-10-12	Methoden zur Herstellung von Protein C
DE60222405D1 (de)	2007-10-25	Verfahren zur verbesserung von proteinprodukten
ATE302214T1 (de)	2005-09-15	Enamel-matrix bezogene polypeptide
DE69530261D1 (de)	2003-05-15	Durch Zelldichte stimulierte Protein-Tyrosin-Phosphatasen